Structure-Guided Discovery of Phenyl-diketo Acids as Potent Inhibitors of M. tuberculosis Malate Synthase  by Krieger, Inna V. et al.
Chemistry & Biology
ArticleStructure-Guided Discovery
of Phenyl-diketo Acids as Potent Inhibitors
ofM. tuberculosisMalate Synthase
Inna V. Krieger,1 Joel S. Freundlich,1,4 Vijay B. Gawandi,1 Justin P. Roberts,1 Vidyadhar B. Gawandi,1 Qingan Sun,1
Joshua L. Owen,1Maria T. Fraile,3 Sofia I. Huss,3 Jose-Luis Lavandera,3,5 ThomasR. Ioerger,2 and JamesC. Sacchettini1,*
1Department of Biochemistry and Biophysics
2Department of Computer Science and Engineering
Texas A&M University, College Station, TX 77843, USA
3Tres Cantos Medicines Development Campus, Diseases of the Developing World, GlaxoSmithKline, Madrid 28760, Spain
4Present address: Departments of Pharmacology and Physiology and Medicine, Center for Emerging and Reemerging Pathogens,
New Jersey Medical School, University of Medicine and Dentistry of New Jersey, 185 South Orange Avenue, Newark, NJ 07103, USA
5Present address: Institute for AppliedMolecular Medicine (IMMA), School of Medicine, UniversidadCEUSan Pablo, CampusMonteprincipe,
Boadilla del Monte, 28668 Madrid, Spain
*Correspondence: sacchett@tamu.edu
http://dx.doi.org/10.1016/j.chembiol.2012.09.018SUMMARY
The glyoxylate shunt plays an important role in fatty
acid metabolism and has been shown to be critical
to survival of several pathogens involved in chronic
infections. For Mycobacterium tuberculosis (Mtb),
a strain with a defective glyoxylate shunt was previ-
ously shown to be unable to establish infection in
a mouse model. We report the development of
phenyl-diketo acid (PDKA) inhibitors of malate syn-
thase (GlcB), one of two glyoxylate shunt enzymes,
using structure-based methods. PDKA inhibitors
were active against Mtb grown on acetate, and
overexpression of GlcB ameliorated this inhibition.
Crystal structures of complexes of GlcB with PDKA
inhibitors guided optimization of potency. A selected
PDKA compound demonstrated efficacy in a mouse
model of tuberculosis. The discovery of these PDKA
derivatives provides chemical validation of GlcB as
an attractive target for tuberculosis therapeutics.
INTRODUCTION
Despite the availability of good first- and second-line thera-
peutics to treat tuberculosis (TB), drug resistance, latency, and
persistence render TB a continuing threat to public health and
pose an urgent need for the development of novel drugs (World
Health Organization, 2011).
The glyoxylate shunt, which plays a central role in fatty acid
metabolism, has long been considered a potential vulnerability
of Mycobacterium tuberculosis (Mtb) that could be exploited
for developing antitubercular therapeutics (McKinney et al.,
2000). The glyoxylate shunt is an anaplerotic bypass of the
traditional tricarboxylic acid cycle that allows for incorporation
of carbon from acetyl-coenzyme A (CoA) produced by fatty
acid metabolism. This pathway is utilized in plants, fungi, and
prokaryotes but is absent in mammals. Mtb has been shown1556 Chemistry & Biology 19, 1556–1567, December 21, 2012 ª2012to undergo significant metabolic alterations during the course
of infection. This includes a shift from a reliance on carbohy-
drates to fatty acids as a principal source of carbon (Bloch
and Segal, 1956). The increased reliance on fatty acid
b-oxidation and gluconeogenesis in concert with a shift away
from glycolysis during infection is supported by analysis of
transcriptional profiles (Schnappinger et al., 2003; Talaat et al.,
2004).
The glyoxylate shunt has been shown to play a crucial role in
Mtb virulence, as isocitrate lyase, the first committed step of
the pathway, is required for infection in activated macrophages
and in animal models (McKinney et al., 2000). The shunt consists
of two enzymes: isocitrate lyase (ICL), which hydrolyzes isoci-
trate into glyoxylate and succinate; and malate synthase
(GlcB), which converts glyoxylate intomalate using onemolecule
of acetyl-CoA. The shunt bypasses two CO2-generating steps of
the TCA cycle, allowing incorporation of carbon (via acetyl-CoA)
and serves to replenish oxaloacetate under carbon-limiting
conditions (Kornberg and Krebs, 1957). Icl1 is one of the most
highly upregulated genes in Mtb under conditions that mimic
infection (Timm et al., 2003). Further studies demonstrated the
essentiality of the glyoxylate shunt for a persistent or chronic
infection by showing that Mtb lacking icl1 was unable to persist
for longer then 3 weeks in a mouse (McKinney et al., 2000).
Furthermore, a knockout of both isoforms of icl could not estab-
lish an infection in mice and was rapidly cleared (Mun˜oz-Elı´as
and McKinney, 2005). A critical role of the glyoxylate shunt for
virulence has been reported for other intracellular and fungal
pathogens (Lorenz and Fink, 2001; Dunn et al., 2009).
Targeting ICL has been a challenge, largely due to its highly
polar and small active site that becomes even more constricted
during catalysis (Sharma et al., 2000). To date, the most widely
used inhibitor of ICL in vitro is the succinate analog, 3-nitropro-
pionate, which has an inhibitory constant (Ki) of 3 mM (Sharma
et al., 2000). In contrast to ICL, GlcB has a much more ‘‘drug-
gable’’ and large active site, consisting of a 20 A˚ 3 7 A˚ cavity,
which normally accommodates the pantothenate tail of the
acetyl-CoA. The catalytic Mg2+ is located at the bottom of
the cavity (Smith et al., 2003; Anstrom and Remington, 2006).Elsevier Ltd All rights reserved
Figure 1. PDKA Inhibitor and Its Contacts to GlcB
(A) PDKA chemical structure drawn here in the enol form most consistent with
solution-phase 1H and 13C nuclear magnetic resonance data.
(B) Diagram of PDKA-GlcB interactions; hydrogen bonds are shown in green.
Catalytic Asp633 contacts the face of the phenyl ring. Coordinating interac-
tions between the Mg2+ ion and oxygens of the inhibitor are in purple. Atom
colors: black, carbon; red, oxygen; blue, nitrogen; green, magnesium. This
figure was made in LigPlot (Laskowski and Swindells, 2011).
See also Figure S2.
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Inhibitors of M. Tuberculosis Malate SynthaseX-ray crystal structures of GlcB bound with substrate glyoxylate
or products CoA and malate (Smith et al., 2003) show that the
protein conformation is nearly identical regardless of the ligand
(root-mean-square deviation [rmsd] < 0.5 A˚), suggesting that
catalysis occurs without significant structural rearrangements.
In this article, we report our structure-based discovery of small
molecule inhibitors of Mtb GlcB and pharmacological validation
of GlcB as a drug target. One of the identified GlcB inhibitors with
a reasonable potency and favorable toxicity, pharmacokinetic
(PK) and pharmacodynamic (PD) profiles, has demonstrated
efficacy in a mouse model of TB and could serve as the basis
for a novel class of antituberculars.
RESULTS
Discovery of PDKA and Crystal Structure
of GlcB-Inhibitor Complex
A focused library of 35 small molecules with a glyoxylate-like
substructure were assayed against GlcB and ICL at a single
concentration point of 40 mg/ml. Of these, 19 showed activity
against GlcB. All of the GlcB active compounds were phenyl-
diketo acids (PDKAs), exemplified by (Z)-2-hydroxy-4-oxo-4-
phenylbut-2-enoic acid (Figure 1A). The parent PDKA exhibited
an IC50 of 2.0 mM against GlcB and was inactive against ICL.
Based on these initial findings, approximately 100 PDKA analogs
were synthesized using readily available starting materials and
straightforward chemical synthesis (Adams, 2008; Pais et al.,
2002; Summa et al., 2004; Tumey et al., 2004; Zeng et al.,
2008). A series of compounds was selected that demonstrated
a good balance of enzyme inhibition and whole-cell activity.
Aryl diketo acids have also been identified in drug discovery
projects for other Mg2+-dependent enzymes. These include
HIV-1 integrase and hepatitis C virus-polymerase, where the
keto acid moiety was found to coordinate the catalytic divalent
metal cation (Egbertson, 2007).
These compounds had IC50s against GlcB ranging from 20 nM
to >100 mM. However, the minimal inhibitory concentrations
(MICs) against cultured mycobacteria were, in certain cases, in
disagreement with the enzyme inhibition level and had poor
reproducibility. A time-dependent decrease of activity was
observed in solutions of inhibitors left at room temperature,
even during short periods of time. UsingUV/visible spectroscopy
(UV/Vis spectroscopy) and high-performance liquid chromatog-
raphy (HPLC) analysis to assess the stability of our compounds,
we found that the parent PDKA was stable in distilled, deionized
water and organic solvents (dimethyl sulfoxide [DMSO], MeOH).
However, it was unstable (t1/2 z 3 days) in cell growth media
or any of several buffer solutions tested. The results from our
HPLC-mass spectrometry (MS) analysis were consistent with
retro-Claisen decomposition, with acetophenone as a product.
We reasoned that the very high degree of conjugation encom-
passing the PDKA molecule was the driver of the retro-Claisen
decomposition, in agreement with previous findings (Egbertson,
2007). To avoid this decomposition, we hypothesized that the
addition of a group to the ortho position of the PDKA phenyl
ring would twist the ring out of plane, reducing the degree of
conjugation. The structure of the GlcB-PDKA complex showed
a 37 degree twist of the phenyl ring of PDKA out of plane with
the conjugated diketo moiety. Therefore, we predicted that theChemistry & Biology 19, 1556–156twist due to substitution should not significantly impact binding
of ortho-substituted PDKAs to the enzyme. Substitution at
the ortho position afforded an approximately 10-fold increase
in compound stability to greater than 30 days and actually
improved the IC50 (Table 1). Identical substitutions at the meta
and para positions had no effect on stability. The extent of conju-
gation of the ortho-substituted phenyl diketo acids in solution
was indeed reduced. This was evidenced by a blue shift of their
respective UV absorbance peaks (lmax values), when compared
to PDKA and meta- and para-substituted compounds (Table 1).
Moreover, the magnitude of this spectral shift correlates with
stability.
All other attempts to stabilize this chemical framework
(removing either of the two keto groups, replacing the carbon
between them with a nitrogen, or introducing a methyl group to
the b carbon of the diketo acid) resulted in compounds that
were inactive against GlcB (data not shown). We evaluated
replacements of the PDKA carboxylic acid by known Mg2+
chelators such as catechol and other bioisosteres such as
tetrazole, but all of these failed to afford GlcB inhibitors with
promising enzyme activity (IC50 > 100 mM).
In the crystal structure of the glyoxylate-bound Mtb GlcB,
Cys619 was oxidized to cysteine-sulfenic acid, similar to E. coli7, December 21, 2012 ª2012 Elsevier Ltd All rights reserved 1557
Table 1. Stability and Activity Data for PDKA Family Inhibitors
Compound R
Half-Life
(days) lmax (nM) IC50 (mM)
MIC99 (mM) for Mtb mc
2 7000
Grown on Acetate
MIC99 (mM) for Mtb mc
2 7000
Grown on Dextrose
PDKA Ph 3 340 2.0 50 25
1 2-MePh 30 326 1.1 >200 200
2 2-FPh 12 333 0.24 >200 200
3 2-ClPh 35 324 0.5 >200 200
4 2-BrPh 18 324 0.6 6.25 12.5
5 3-MePh 11 339 0.18 25 50
6 3-ClPh 7 341 0.17 25 25
7 3-BrPh 7 341 0.8 25 25
8 4-MePh 8 340 6.0 50 100
9 4-BrPh 7 345 5.7 50 25
10 2-Cl-6-FPh >30 317 2.7 50 100
11 2-Cl-6-F-3MePh >30 321 5.5 50 100
See also Table S1 and Figures S1 and S5.
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Inhibitors of M. Tuberculosis Malate Synthasemalate synthase (Anstrom et al., 2003), resulting in a constriction
at the entrance to the active site channel. The sulfenic acid is an
artifact resulting from exposure to air during purification and is
not relevant to the metabolic function of GlcB (Quartararo and
Blanchard, 2011). We therefore constructed a Cys619Ala Mtb
GlcB mutant, which exhibited 80% of the reaction velocity of
the wild-type (kinetic curve shown in Figure S1 available online).
It also exhibited a 10-fold increase in acetyl-CoA KM (from 5 to
50 mM). Examination of the crystal structure of GlcB bound to
CoA (1N8W; Smith et al., 2003) shows that the Sg of Cys619
forms a hydrogen bond with a nitrogen in the pantothenate
arm of CoA. This could explain why the C619A mutant enzyme
binds the cofactor with lower affinity, potentially causing the
slight reduction in reaction velocity. A similar Cys619Ser Mtb
GlcB mutant has also been described as a suitable model for
kinetic studies (Quartararo and Blanchard, 2011). However,
with the Cys619Ala mutant, we did not observe the lag in activity
reported for the Cys619Ser mutant. Furthermore, elevating Mg2+
concentrations did not influence the activity (Figure S1). Since
the IC50 values of inhibitors measured for the mutant and wild-
type enzymes were well correlated (see Table S1; cf. Table 1),
the C619A mutant protein was used in all subsequent crystallo-
graphic studies and enzyme assays. Cys619 is located 5 A˚
away from the ligand (as shown in Figure S2) and thus does
not participate significantly in binding of these inhibitors.
The crystal structure of GlcB (C619A) complexed with PDKA
was determined at 1.9 A˚ resolution (data collection and refine-
ment statistics are presented in Table 2). No significant confor-
mational changes in the protein were observed upon PDKA
binding compared to structures with glyoxylate or malate and
CoA bound. The backbone rmsd of the superposition between
the GlcB:malate complex and the GlcB:PDKA complex is
0.32 A˚ over 700 Ca atoms. Among 15 active site residues, the
all-atom rmsd is 0.21 A˚, excluding Met631, which adopts
a different conformation to accommodate the phenyl ring. The
diketo acid group of the PDKA coordinates the Mg2+ ion in an
edge-on fashion, very similar to that of glyoxylate (Smith et al.,
2003). The inhibitor fills two of the six octahedral coordination
sites with one of the carboxylate oxygens and the adjacent1558 Chemistry & Biology 19, 1556–1567, December 21, 2012 ª2012ketone oxygen (2.1 A˚ and 2.2 A˚ contact distances, respectively).
Other active site interactions are illustrated in Figure 1B.
Carboxylate oxygens of the inhibitor hydrogen-bonded with
the backbone nitrogens of Asp462 and Leu461 (dO-N = 3.0 and
3.0 A˚, respectively). Both ketone oxygens also form hydrogen
bonds (dO-N = 2.9 and 2.9 A˚) with the Arg339 side chain, exhib-
iting similar contacts as the substrate and product. The catalytic
Asp633 (Clark et al., 1988) side chain oxygen was within
hydrogen-bonding distance (3.2 A˚) to the phenyl ketone oxygen
of PDKA. As noted earlier, the aryl ring of the PDKAs was twisted
37 out of coplanarity with the ketone. It occupied the approxi-
mate middle of the active site channel, overlapping the region
where the thiol group of CoA normally binds. The aromatic ring
formsmultiple van derWaals interactions with the Cg of catalytic
Asp633 and the side chains of Met515, Trp541, and Met631.
The carboxylate of the side chain of Asp633, which is expected
to be deprotonated in view of its catalytic function (Clark et al.,
1988), is positioned over the face of the PDKA ring. The carbox-
ylate is slightly shifted toward the diketo acid side, with
distances from Od1 to PDKA atoms C1 and C6 of 4.1 and
3.4 A˚, respectively, and from Od2 to C1 and C2 of 3.3 and
4.0 A˚, respectively.
The close contact between the Asp633 side chain and the aryl
ring of the inhibitor is unusual. It resembles anion-p interactions
that have recently been reported in small molecules and proteins
(Berryman et al., 2007; Schottel et al., 2008). In most interactions
between anions and aromatic groups in biomolecular systems,
the anion contacts the aromatic ring on the edge (coplanar)
with distances of 4.5 A˚. In contrast, the contacts of carboxyl-
ates over the center of the ring are generally >5.0 A˚ (Jackson
et al., 2007; Philip et al., 2011). However, face-on anion-p
contacts have been observed in inorganic systems and are
enhanced by electron-withdrawing substituents, resulting in
lower contact distances and higher binding affinities. This is sup-
ported by semiempirical quantum mechanics calculations for
representative model systems that suggest there is a significant
energy well for face-on contacts at 3–4 A˚ (Berryman et al., 2007;
Schottel et al., 2008). All crystal structures of GlcB-inhibitor
complexes with PDKA analogs we have solved to date exhibitElsevier Ltd All rights reserved
Figure 2. Anion-p Interaction
PDKA inhibitor (4) with Asp633 superimposed with crystal structure of TCB in
complex with NaI (606750 entry at Cambridge Crystallographic Data Center as
supplementary for small molecule anion-p complex structures; Berryman
et al., 2007) colored by element, TCB ring is slightly offset for easier visuali-
zation. Halide shown as a purple sphere, TCB carbons are indicated as yellow;
Asp633 with gray carbons represent Asp633 position in complex with single
ortho-halogen-substituted PDKAs (o-Br-PDKA shown), while Asp633 with
black carbons represent Asp633 position for all other complexes (with PDKA,
1, 7, and 11). Atom colors: black, gray, or yellow, carbon; red, oxygen; blue,
nitrogen; white, hydrogen; purple, iodine. Images are rendered in CHIMERA
(Pettersen et al., 2004).
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face of the aromatic ring of the inhibitor. Among the five struc-
tures reported in this article, the mean distance between the
closest arene carbon and either of the Asp633 oxygens is
3.1 A˚, with a mean contact angle of 55 relative to the ring
plane. This is consistent with a face-on interaction. A superpo-
sition of the ring plane of the Asp633-PDKA pair with the small-
molecule crystal structure of tetracyanobenzene (TCB) com-
plexed with iodide (NaI) reported by Berryman et al. (2007)
(Figure 2) shows a very similar configuration between the two
systems. The anion of the TCB-NaI complex (iodine) superim-
poses on the carboxylate of Asp633 in the GlcB-PDKA struc-
tures and is located over the periphery of the ring (the carbon
connecting to the diketo acid moiety), rather than directly over
the ring center as suggested by theoretical calculations (Schot-
tel et al., 2008). Presumably, this position provides additional
localized polarization. Anion positioning over the periphery of
the ring rather than over the center has been hypothesized to
indicate a partial charge-transfer character to the interaction
(Berryman et al., 2007). In single ortho-halogen-substituted
PDKAs (represented in Figure 2 by o-Br-PDKA) bound with
GlcB, Asp633 is shifted away from the halogen by 1.7 A˚
(measured at Od2), reflecting the asymmetry created by the
electron-withdrawing group. In contrast, with the symmetric
double ortho-halogen-substituted PDKA, the carboxylate of
Asp633 is in the same position as with unsubstituted PDKA or
o-Me-PDKA (Figure 2).
Given the extra room in the active site around the phenyl ring of
the PDKA, we hypothesized that an alternative cyclic structure
could be accommodated and might improve affinity. Several
replacements for the phenyl ring in PDKA were prepared,
including aliphatic moieties, exemplified by cyclohexyl and
adamantyl cores. But these were found to be inactive againstChemistry & Biology 19, 1556–156GlcB (data not shown), suggesting a strong requirement for an
aromatic moiety. Other aromatic rings such as naphthyl and
various heterocycles were evaluated but were not immediately
pursued due to a suboptimal combination of enzyme inhibition,
whole-cell activity against cultured mycobacteria, and pharma-
cokinetic profile (full structure-activity relationship [SAR] data
to be published elsewhere). Naphthyl-, indole-, pyrrole-, and
thiophene-based diketo acids were active against the enzyme
with IC50s ranging from 20 nM to 5 mM. However, the first three
did not exhibit adequate whole-cell activity, and thiophenes
had only low whole-cell activity (R50 mM) (attributed to albumin
binding) (data not shown). Furan-, quinoline-, benzodioxole-, and
benzothiazole-based PDKAs exhibited low enzyme inhibition
activity (IC50s ranging from 30 to 100 mM). Thiazole-, pyridine-
and pyrimidine-based PDKAs were inactive against the enzyme
(data not shown).
Structure-Guided Optimization of PDKA Analogs with
High Potency
Structural examination of the GlcB-PDKA complex suggested
several opportunities to enhance affinity by making substitutions
around the PDKA aromatic ring to optimize interactions within
the active site (a schematic view of substitution strategy is
shown in Figure S3). Because of their importance for stability,
we focused on optimizing the potency and whole-cell activity
of ortho-substituted PDKAs. Crystal structures of complexes of
GlcB with 20 of the synthesized PDKA analogs were determined
at resolutions ranging from 1.8 to 2.2 A˚ to evaluate whether
binding modes agreed with our predictions and to guide new
ideas (crystallographic statistics for five representative data
sets are shown in Table 2; an example of omit map density is
shown in Figure S2). The crystal structure of GlcB in complex
with 2-Br-PDKA (4) showed that the Br oriented toward the
Val118 side chain (Figure 3A). The potency of the ortho-sub-
stituted analogs was improved compared to unsubstituted
PDKA (2.0 mM). The most potent were those with halogens,
with a preference for smaller groups: 2-F (0.24 mM) < 2-Cl
(0.5 mM) < 2-Br (0.6 mM) < 2-Me (1.1 mM) (Table 1). This was
presumably due to the increase of steric clashes with the
Val118 side chain (3.2 A˚ from Br to the closest Cg of Val118).
There is little space available to accommodate a larger group.
Indeed, o-Et-PDKA showed an IC50 of only 35 mM. Crystal
structures of ortho-substituted PDKA complexes with GlcB
indicated that all the ortho substituents orient in the same
direction i.e., none are rotated to position 6 (Figure 1A), regard-
less of their size or nature. The ring of the ortho-substituted
PDKA does not overlap exactly with the position of the parent
PDKA ring (Figure 3). For all of 2-substituted inhibitors, it is
moved about 0.7 A˚ away from Val118 to accommodate the
group at the 2 position.
There was less room in the pocket off the 6 position of the aryl
ring compared to the 2 position of the bound PDKA (3.9 A˚ to
Leu461 compared to 4.4 A˚ to Val118). This is likely the reason
why the double ortho-substituted compound 2-Cl-6-F (10)
(IC50 = 2.7 mM) did not show better inhibition of the enzyme
than PDKA (IC50 = 2.0 mM). However, we cannot rule out the
possibility of an unfavorable alteration in the ring’s charge
distribution compared to a single ortho-substituent affecting
interaction with Asp633 (Figures 3A and 3B).7, December 21, 2012 ª2012 Elsevier Ltd All rights reserved 1559
Table 2. Crystal Data Collection and Refinement Statistics
Statistic
GlcB Complex with
PDKA
GlcB Complex
with 4
GlcB Complex
with 1
GlcB Complex
with 7
GlcB Complex
with 11
Data Collection
Space group P43212 P43212 P43212 P43212 P43212
Cell Dimensions
a, b, c (A˚) 79.33, 79.33,
225.94
79.45, 79.45,
226.26
77.74, 77.74,
221.98
78.22, 78.22,
223.58
78.49, 78.49,
224.05
a, b, g () 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90
Resolution (A˚) 50–1.90 (1.93–1.9) 43.05–1.80
(1.83–1.80)
44.13–1.82
(1.92–1.82)
49.57–2.04
(2.13–2.04)
45.59–2.20
(2.24–2.20)
Rsym or Rmerge 0.109 (0.532) 0.191 (0.634) 0.108 (0.554) 0.099 (0.584) 0.183 (0.742)
I/sI 13.8 14.0 6.4 6.3 9.0
Completeness (%) 99.9 (99.4) 97.2 (76.0) 99.9 (100) 99.2 (98.6) 99.9 (100)
Redundancy 13.1 (10.2) 9.5 (2.6) 9.7 (9.8) 15.3 (15.4) 14.4 (14.8)
Refinement
Resolution (A˚) 50–1.90 43.05–1.8 44.13–1.82 49.57–2.04 45.59–2.2
No. of reflections 57789 66563 62029 45023 36507
Rwork/ Rfree 0.168/0.203 0.175/0.219 0.170/0.220 0.163/0.204 0.172/0.223
No. of atoms
Protein 5,543 5,645 5,562 5,509 5,429
Ligand/ion 14/3 15/3 15/3 15/3 17/3
Water 674 859 641 574 400
B factors
Protein 27.86 29.64 21.22 32.13 34.69
Ligand/ion 30.47/28.14 20.7/32.13 14.24/27.53 30.1/38.4 28.87/39.3
Water 39.65 40.55 28.79 38.58 40.78
Rmsd
Bond lengths (A˚) 0.013 0.007 0.007 0.007 0.008
Bond angles () 1.03 1.024 1.013 1.013 1.062
Data restricted to highest resolution shell are shown in parentheses. All crystals were of the C619A mutant enzyme with His6 tag.
See also Figure S2.
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Met631 side-chain (3.6 A˚ to Met631 Cg) (Figures 3A and 3B).
Therefore, accommodation of a substituent at this position
requires the Met631 side chain to assume a different conforma-
tion. Indeed, 4-Me and 4-Br PDKA analogs (8 and 9) showed
higher IC50 values than parent PDKA (5.7 and 6.0 mM, re-
spectively), likely due to steric interference with the Met631
side chain.
The structure of the PDKA bound to GlcB showed that position
3 of the aromatic ring was the most promising for extending the
PDKA. Any extension should align with the long axis of the
channel where the substrate acetyl-CoA binds (Figure 3). This
offered the possibility of exploiting the pantothenate binding
contacts. These include a hydrogen bond with the backbone N
of Val119, and van der Waals interactions with the side chains
of Met631,Met515, and the backbone of Val118-Val119. Indeed,
analogs with substitutions at the meta position showed the
largest improvement in potency over PDKA. The most active
compounds were 3-Cl-PDKA (6, IC50 = 0.17 mM) and 3-Me-
PDKA (5, IC50 =0.18mM). Thecrystal structure ofGlcB in complex
with the 3-Br-PDKA (IC50 = 0.8 mM) (7) showed the Brmaking van
der Waals contacts, sandwiched between the side chains of1560 Chemistry & Biology 19, 1556–1567, December 21, 2012 ª2012Met515 and Met631, arranged on opposite sides of the channel.
It is interesting to note that, although sufficient space seemed to
exist in the channel to accommodate longer substitutions at the
meta position, alkyl and (CH2)nAr (n = 1, 2; Ar = aryl) substitutions
at that position resulted in inhibitors with poor enzyme activity
(IC50 > 100 mM). This may be attributed to a suboptimal angle
at which the meta substituents project off the phenyl ring. This
could potentially result in steric clashes with either Met631 or
with Val119 and Pro120 on the other side of the channel.
The substituent’s effect on the electronic properties of the
aromatic ring of PDKA appeared to be critical for inhibition
activity. This is likely due to their influence on ring p-interactions
with the carboxylate of catalytic Asp633. For example, 2-Cl-6-F
substituted PDKA (10) has an IC50 of 2.7 mM. In contrast, 2,6-
Me-PDKA, which is of similar size and substitution positioning
but not as electron withdrawing, was inactive, with an IC50 >
100 mM. Although the activity of compounds with halogens
substituted at the 3 position had better enzyme activity than
analogs substituted at the 2 position (e.g., 0.5 mM IC50 for 2-Cl-
PDKA versus 0.17 mM for 3-Cl-PDKA), there was a tradeoff with
stability. Two-substituted compounds exhibited longer half-
lives. Since stability was important for whole-cell assays andElsevier Ltd All rights reserved
Figure 3. Comparing Binding of PDKA Analogs to GlcB
(A and B) Binding of GlcB to inhibitor 4 (A) and inhibitor 11 (B) colored by element, with Cprotein in gray and Cligand in black. Hydrogen bonds are indicated by solid
blue lines, and distances from key positions on the phenyl ring to protein residues are marked as dashed lines.
(C) Crystal structure overlay of GlcB complexed with PDKA (in magenta); 1, 4, 7, and 11, represented by ball-and-stick, and CoA, represented by a stick model
(colored by element), with the Mg atom in green, illustrate the relative positions of the ligands occupying the active site channel (presented by protein surface
calculated in CHIMERA (Pettersen et al., 2004). The CoA model and protein surface were made from chain A of the 2GQ3 model.
See also Figure S3.
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tutions. Trisubstituted 2-Cl-6-F-3-Me-PDKA (11) did not result in
an additive affinity of each position (IC50 = 5.5 mM). However, 11
proved to be a goodcandidate for future study, as itsmethyl ester
derivative exhibited a good combination of essential features
(reasonable potency, high bioavailability, low toxicity) to test for
efficacy in an animal model of TB infection.
Antimycobacterial Activity of PDKA Inhibitors
We carried out whole-cell testing of growth inhibition by PDKAs
on 0.2% acetate-supplemented M9 media to model fatty
acid-driven metabolism and 0.2% dextrose-supplemented 7H9
media to model carbohydrate-oriented metabolism for com-
parison. Initial testing was conducted with a Biosafety Level 2
(BL2)-approved vaccine strain of Mtb with deletions of the
panCD genes and the RD1 region (mc2-7000) (Sambandamurthy
et al., 2006). Freshly synthesized inhibitors were solubilizedChemistry & Biology 19, 1556–156immediately prior to MIC determination (presented in Tables
1 and 3). Almost all of the PDKA inhibitors with reasonable
potency against the enzyme inhibited growth of bacteria on
acetate. Furthermore, they were less potent on carbohydrate
(dextrose), with MICs usually 2- to 4-fold higher than on acetate,
suggesting that they affect the glyoxylate shunt. In the context of
this article, MICs are reported as MIC99, which refers to the
minimum concentration of a compound at which bacteria growth
is inhibited by >99%, as assessed by absence of respiration in
the rezasurin (AlamarBlue) assay. Testing on other tuberculosis
strains and clinical isolates has not yet been carried out.
To improve whole-cell activity, we used a prodrug strategy by
masking the acid via esterification as a way to enhance cellular
uptake. Simple alkyl esters of whole-cell-active PDKA analogs
had approximately 8-fold lower MICs compared to their corre-
sponding PDKAs (Table 3). Of particular interest were the
ester prodrugs of the ortho-bromo (4), ortho-methyl (5), and7, December 21, 2012 ª2012 Elsevier Ltd All rights reserved 1561
Table 3. H37Rv Activity, Mouse Plasma Protein Binding, andMouseMicrosomes Clearance Data for Alkyl- and Benzyl-ester Prodrugs
of Selected PDKA Analogs
Compound
H37Rv MIC99 on
Acetate (mM)
H37Rv MIC99 on
Dextrose (mM)
Mouse Microsomes Clearance
(ml/min/g)
Mouse Plasma Protein
Binding (%)
11 16 32 <0.3 70 ± 3.0
Me ester of 11 (12) 2 8 0.6 ± 0.2 91.9 ± 1.6
Benzyl ester of 11 <1 2 >30 ND
4 16 32 <0.3 67.5 ± 2.6
Me ester of 4 8 16 3.2 ± 0.7 87.7 ± 1.6
Benzyl ester of 4 <1 8 15.3 ± 6.1 ND
1 16 32 ND 70.7 ± 1.8
Me ester of 1 4 16 4.6 ± 0.7 87.1 ± 1.4
Benzyl ester of 1 <1 16 >30 ND
See also Tables S1 and S3.
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values in the%1 to 8 mM range against H37Rv grown on acetate
as a carbon source (Table 3). In agreement with earlier data
on the Mtb mc2-7000 strain, PDKA esters inhibited growth
of the H37Rv strain on dextrose-supplemented media with
2- to 4-fold higher MICs. In addition, Caco-2 uptake studies
(Yazdanian et al., 1998) demonstrated the enhanced perme-
ability of esters compared to their corresponding acids. Perme-
ability ranged from a nondetectable level for acid 11 to a high
level of 371 nm/s for the corresponding methyl ester 12). This
suggests they could potentially be orally bioavailable and
taken up through the gut. Following the decomposition of the
benzyl- and methyl esters of 11 in whole-cell lysates over time
by MS demonstrated accumulation of acid 11 and no other
product (Table S2). As expected, none of the PDKA esters them-
selves were directly active against GlcB in the enzyme assay.
However, upon hydrolysis with longer preincubation, each ester
decomposed to yield the parent PDKA (free acid) active against
the enzyme. Furthermore, PDKA esters inhibited malate syn-
thase activity in mycobacterial cell lysates (Tables S1 and S2).
These compounds achieved IC50s in whole-cell lysates similar
to the purified enzyme assay. No loss of inhibition was observed
even after 3 hr of incubation due to potential reactivity or binding
to other proteins. This argues that these compounds act on GlcB
inside the cell (Table S1).
The methyl ester of 11 (12) was tested using the standard
minimal bactericidal concentration (MBC)determinationprotocol
(Motyl et al., 2006). It was shown to bebactericidal tomc2-7000 in
culture on either acetate or dextrose carbon sources. The MBC
was approximately the same as theMICwhen grown on acetate.
The MBC was 2- to 4-fold higher than the MIC on dextrose.
Compound 12 was also tested in the Low-Oxygen Recovery
Assay (LORA) and was found active against H37Rv grown on
dextrose (MIC = 52 mM). LORA is one of the in vitro models of
the nonreplicating drug-tolerant state of Mtb (Cho et al., 2007).
The observed 4- to 5-fold shift of MIC in the LORA assay
compared to the MABA assay (Microplate Alamar Blue Assay;
Franzblau et al., 1998) (MIC = 11 mM) is consistent with what
has been observed for other antitubercular drugs with activity
against nonreplicating bacteria, such as rifampicin (Cho et al.,
2007).1562 Chemistry & Biology 19, 1556–1567, December 21, 2012 ª2012To confirm that GlcB is the intracellular target responsible for
growth inhibition inMtb, we constructed a GlcB-overexpressing
strain inMtb containing a plasmid with either GlcB under a tetra-
cycline-inducible promoter or an unrelatedMtb protein (Rv3547)
as a control. An 8-fold increase in the MIC for 12 (12.5 to 100 mM)
was observed after induction of GlcB expression using anhydro-
tetracycline on M9 media with acetate. A 4-fold increase in the
MIC (25 to 100 mM) was observed on 7H9-dextrose. In contrast,
the strain with the control plasmid (Rv3547) showed no shift in
MIC for compound 12. All strains displayed the same MIC for
rifampicin (with or without anhydrotetracycline) as the untrans-
formed parental strain. The observed increase in the MIC for
compound 12 in response to GlcB overexpression strongly
supports on-target activity. In addition, we have tested PDKA
inhibitors (4 and 11) at a high concentration of 100 mM on four
purified enzymes in the core metabolic pathways from Mtb
which react with similar substrates (ICL, phosphoenolpyruvate
carboxykinase, isocitrate dehydrogenase, and pyruvate kinase)
and observed no inhibition (data not shown). This adds to reas-
surance that inhibition is specific to GlcB.
Inhibition of GlcB in a Murine Model of TB
We evaluated the pharmacologic properties of several of the
most potent inhibitors and selected a representative for
evaluation in a mouse model of TB infection. The most important
factors we considered were solubility, chemical stability, plasma
protein binding, serum stability, metabolic clearance in micro-
somes, and pharmacokinetic profile. The ADME (absorption,
distribution, metabolism, excretion) guidelines we used were:
solubility in PBS at >20 mg/ml, stability in human and murine
plasma >70% over 1 hr, clearance in mouse microsomes after
30 min < 15 ml/min/kg, and Caco-2 permeability > 100 nm/s.
The methyl ester 12 showed the best combination of potency
with in vitro PKproperties among thePDKAanalogs tested (Table
3) and, therefore, was selected for further in vivo PK, PD, and
toxicity studies. In mice, 12 was orally bioavailable (%F = 92)
and attained sufficient blood levels (i.e., at 600 mg/kg dosing:
Tmax = 0.25 hr, Cmax = 99.5 mg/ml, and AUC8 hr = 54.3 mg 3 hr/
ml).12demonstratedgoodstability inCD1mouseplasma, exhib-
iting slow hydrolysis of the ester to yield the parent PDKA deriva-
tive (t1/2 = 30 min, conversion from 12 to 11 in plasma). TheElsevier Ltd All rights reserved
Table 4. Therapeutic Efficacy of 12 against Mtb in Mice
Compound Target Dose (mg/kg) Experimental Dose (mg/kg) Administration (per day) Decrease in log10 CFU in Lungs
a SE
Moxifloxacin 30 36 Once 3.07 0.064
12 500 542 Once 1.68 0.103
12 600 718 Once 1.72 0.149
12 300 377 Twice 1.89 0.079
12 400 460 Twice 2.12 0.108
Five animals in each testing group were inoculated with 105 CFU ofMtb intratracheally, and treatment started 1 day postinfection. Nine days postin-
fection, the mice were sacrificed, and the respective bacterial loads in the lungs were determined.
See also Figure S4.
aAll reductions in CFU were statistically significant over the untreated control group by a t test (df = 9,10; p < 0.0001).
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a mouse liver microsome assay (<0.3 ml/min3 g), and a reason-
able level of mouse plasma protein binding (70%). (The eventual
disposition of 11, whether by metabolism or excretion, was not
determined in vivo.) The achieved exposure for 12 in mice,
as measured by AUCfree/MICH37Rv/acetate (35 at 600 mg/kg
oral dosing), compared reasonablywell to clinical antituberculars
such as moxifloxacin (AUCfree/MICH37Rv/acetate = 142 at 100 mg/
kg oral dosing). (PK curves for 12 and its activated form 11 are
shown in Figure S4.) The PK data show that the peak blood
concentration achieved for compound 12 at 300, 500, and
600 mg/kg was approximately 150- to 200-fold higher than the
MIC for H37Rv (2 mM = 0.548 mg/ml). The exposure was main-
tained above the MIC value for at least 6–7 hr. Assessment in
C57BL/6J mice with a single-dose oral administration of 12
formulated in Solutol (30%) and PEG 400 (70%) demonstrated
that a dose of 1,000 mg/kg (the highest tested) was not lethal.
The maximum tolerated dose (MTD) was determined to be
600 mg/kg. No toxicity effects were observed at 400 mg/kg
p.o. twice daily.
Compound 12was tested in amurine model of acute TB infec-
tion (Rullas et al., 2010). C57BL/6J mice were infected intratra-
cheally with 105 colony-forming units (CFU) and treated for
9 days, followed by determination of bacillary load in the lungs.
Several dosing strategies from 300 to 600 mg/kg were tested
to determine the best compound exposure above the MIC at
or below the MTD established. Treatment with moxifloxacin
(30 mg/kg), which is used in the treatment of multidrug-resistant
tuberculosis (Cox et al., 2011), was used for comparison. At all
dosing levels (once daily [u.i.d.] and twice daily [b.i.d.]), 12 ex-
hibited a statistically significant reduction (p values < 0.0001) in
the Mtb bacterial load compared to the control (Table 4). In
fact, at 400 mg/kg b.i.d. dosing, 12 reduced the bacterial load
by over 100-fold (Dlog10 CFU = 2.12), within an order of magni-
tude of moxifloxacin (Dlog10 CFU = 3.07). This activity was
achieved despite the fact that the dosage, which was limited by
the MTD, provided exposure well above the MIC for only 6–8 hr
at a time. Thus, inhibition of GlcB resulted in impairment of the
ability to establish an acute infection inmice, similar to the results
obtainedwith aDicl1/2 strain (Mun˜oz-Elı´as andMcKinney, 2005).
DISCUSSION
Our studies have shown that malate synthase is essential for
Mtb survival both in vitro and in vivo, and this enzyme can beChemistry & Biology 19, 1556–156targeted with PDKA inhibitors. Structure-guided design led
to the identification of highly potent inhibitors, some with sub-
micromolar IC50s. While the acids in the series displayed diffi-
culty penetrating the cell wall, esters of these compounds acted
as prodrugs that could be taken up and hydrolyzed inside
cells, leading to potent growth inhibition. Overexpression of
the enzyme leads to a 4–8-fold increase in MIC for these
compounds—evidence that GlcB is the target whose inhibition
is responsible for cell death. Furthermore, we observed a corre-
lation in structure–activity relationship, where analogs with
different substituents around the PDKA core that inhibit the
enzyme (or their corresponding esters) also inhibit whole-cell
growth, and analogs with substituents that abrogate activity
against the enzyme are also inactive against whole cells. This
correlation of SAR would be highly improbable if the actual
target of these compounds inside the cell were an enzyme other
than GlcB. Finally, the compounds are consistently 4-fold more
potent in cultures grown on acetate as a carbon source com-
pared to dextrose conditions. Based on these observations,
we conclude that inhibition of GlcB is the mechanism of action
of the PDKAs in vivo.
The observation that inhibitors of GlcB are bactericidal forMtb
grown on carbon sources other than fatty acids, such as carbo-
hydrates like dextrose, was unexpected because inactivation of
ICL is tolerated when grown in vitro on carbohydrates (McKinney
et al., 2000). Since ICL2 also has partial isocitrate lyase activity
(Gould et al., 2006), aDicl1/icl2 doublemutant ofMtb completely
lacking a functional glyoxylate shunt was constructed and was
also found to be able to grow on dextrose (Mun˜oz-Elı´as and
McKinney, 2005). However, the Dicl1/icl2 double mutant grew
at a suppressed rate (2- to 4-day lag), suggesting that the glyox-
ylate shunt might be playing a metabolic role even when Mtb is
growing on carbohydrates. Unlike E. coli and other well-studied
bacteria, which suppress anaplerosis in the presence of a
preferred carbon source like carbohydrates (Fischer and Sauer,
2003), Mtb catabolizes carbohydrates and fatty acids concur-
rently in vitro with no apparent repression (de Carvalho et al.,
2010). Supporting the observation that GlcB is essential
in vitro, recent high-density transposon-mutagenesis experi-
ments have shown that glcB is essential for growth on glycerol
as well as cholesterol as a carbon source (Griffin et al., 2011).
One possible explanation for the requirement for GlcB could
be to avoid accumulation of glyoxylate. Glyoxylate has been
shown to be toxic in other bacteria (Nun˜ez et al., 2001). However,
Mtb is able to grow on glyoxylate as a sole carbon source (our7, December 21, 2012 ª2012 Elsevier Ltd All rights reserved 1563
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glycine dehydrogenase or glyoxylate aminotransferase) that
can utilize glyoxylate as a substrate (Sakuraba et al., 2008;
Wayne and Lin, 1982). In addition, we found, that, when the ICL
inhibitor 3-nitropropionate (3-NP) is coadministered at a low
sub-MIC concentration (20 mM) with GlcB inhibitors to Mtb
cultures grown on 7H9-dextrose media, it causes a decrease in
MIC (e.g., from12.5mMto1.56mMfor12). In theory, the presence
of 3-NP should reduce glyoxylate accumulation by suppressing
flux through the glyoxylate shunt and would thus be expected
to cause an increase in MIC for GlcB inhibitors. The decrease
in MIC we observed suggests that the requirement for GlcB
in vitro under carbohydrate-supplemented growth conditions
might not be limited to a need for glyoxylate detoxification.
There are several alternative reasons why GlcB inhibition
under carbohydrate-supplemented growth conditions might
result in cell death. Functional GlcB might be required when
grown on dextrose to replenish the intermediates on the reduc-
tive side of TCA cycle (succinate, malate, and oxaloacetate).
These were shown to be maintained at relatively low intracellular
concentrations by metabolite tracing (de Carvalho et al., 2010).
A recent analysis of 13C metabolic flux in Mtb demonstrated
a constant flux through the glyoxylate shunt, even with glycerol
as a carbon source. Furthermore, disruption of icl1 resulted in
a loss of viability at a slow growth rate (Beste et al., 2011). This
echoes the finding of ICL1’s importance toMtb’s ability to adapt
to nutrient-limiting conditions by regulating ATP levels required
for entering a nonreplicating state (Gengenbacher et al., 2010).
These data point to the conclusion that the role of the glyoxylate
shunt extends beyond its anaplerotic function in Mtb. Despite
the uncertainty about its metabolic role under carbohydrate-
supported growth conditions, our results make it clear that inhi-
bition of GlcB is lethal toMtb grown on multiple carbon sources,
and this provides a route to antitubercular drug development.
SIGNIFICANCE
Novel enzyme targets are needed to drive discovery of new
drugs for combating tuberculosis. Because of its role in the
glyoxylate shunt, we have investigated malate synthase
(GlcB) as an attractive target and identified a series of potent
inhibitors with a phenyl-diketo acid (PDKA) scaffold. A
selected compound (12) in the PDKA series was shown to
have efficacy in a mouse model of infection. While complete
sterilization was not achieved, the bacterial load was
reduced nearly 100-fold over the course of 9 days. It is inter-
esting that the compound appears to be active during the
acute phase of infection, which is consistent with the essen-
tial role of GlcB for growth on other carbon sources in
addition to fatty acids. Thus, these compounds have the
potential to have activity during both acute and chronic
phases of infection. It is likely that with further optimization,
a more potent compound than 12 (which was chosen for
a tradeoff of pharmacokinetic/pharmacodynamic proper-
ties) would be able to achieve even higher bacterial clear-
ance in vivo. Nonetheless, the statistically significant
reduction of the bacterial load observed indicates that the
PDKA compounds could have therapeutic potential and
provides evidence that Mtb GlcB could be a clinically rele-1564 Chemistry & Biology 19, 1556–1567, December 21, 2012 ª2012vant target. These structural studies will form the foundation
for development of better GlcB inhibitors to be used eventu-
ally in human clinical trials.
EXPERIMENTAL PROCEDURES
Protein Overexpression and Purification
GlcB with the Cys619 mutated to Ala was cloned into a custom vector p6HisF-
11d, expressed in E. coli BL21 cells, and purified by Ni affinity and size ex-
clusion columns as described previously (Smith et al., 2003). As the presence
of the His-tag did not change the results of the enzyme assay or crystallization,
most of the reported work was done using GlcB with the N-terminal His-tag
intact.
DTNB-Coupled Enzyme Assay
For the C619AGlcBmutant enzyme, a DTNB-coupled assay was used to eval-
uate inhibition activity. A BMG POLARstar OPTIMA plate reader was used to
determine the inhibition of GlcB by continuously monitoring the formation of
CoA in the forward enzymatic reaction by the increase in absorbance at
412 nm due to 5,50-dithiobis-(2-nitrobenzoic acid) (DTNB)-CoA adduct forma-
tion, over a period of 20 min. The 96-well plates contained 100 ml total reaction
volume with 13 nM C619A GlcB in the reaction buffer (20 mM Tris, pH 7.5, and
5 mM MgCl2). All inhibitors (in 100% DMSO) were added such that the final
reaction mixture contained 1% DMSO. Inhibitors were incubated with GlcB
in the reaction buffer for 20 min at room temperature before adding 0.6 mM
acetyl-CoA. The reaction was initiated by the addition of 1.2 mM glyoxylate
and 0.5 mM (final concentration) DTNB. Each data point for the IC50 plots
was measured in triplicate. The data reported in this article reflect the most
robust enzyme assay conditions. We noticed that a longer preincubation
time with GlcB (probed up to 3 hr), and lower Mg2+ concentrations in the assay
buffer (1–5 mM, still in vast excess to the KM for this metal ion as a cofactor in
the reaction) led to enhanced enzyme inhibition for the PDKA family of
inhibitors (relative to control reactions of the enzyme incubated for the same
duration, in the same Mg2+ concentrations without inhibitor in each case,
which corrects for the slight loss of activity of the enzyme over time due to
protein instability). It appears that PDKA inhibitors are slow to reach equilib-
rium binding, probably because they bind through chelating Mg2+ in the
same manner as glyoxylate (Copeland, 2005). However, incubating longer
than 30 min at room temperature led to a decrease in enzyme velocity and
reduced assay reproducibility and was not done for routine inhibitor testing
aiming at building SAR.
Pyruvate-Dehydrogenase-Coupled Assay
For thewild-typeGlcB enzyme, this assaywas used because theCys619 in the
active site is sensitive to oxidation by the DTNB in the coupled reaction.
Velocity was measured by monitoring the increase of fluorescence (excitation
at 340 nm, emission at 480 nm) due to NADH production coupled with the
release of CoA. Final concentrations in the reaction mixture were: 3 nM of
GlcB, 0.1 UI/ml of pyruvate dehydrogenase (PDH), 50 mM glyoxylate, 2 mM
acetyl CoA, 500 mM NAD, 500 mM pyruvate, 200 mM thiamine pyrophosphate,
5 mM MgCl2, 0.8 mM EDTA, 50 mM Tricine pH 7.4. EDTA was included in the
assay buffer in both assays because it enhances the stability of the enzyme
and does not affect the enzyme velocity, although it is over 6-fold lower than
the concentration of Mg2+ used. The same assay was used in mycobacterial
cell lysate (1 mg/ml total protein concentration measured by Bradford assay),
with cells harvested at midlog phase and disrupted by sonication.
Inhibitor Synthesis
Chemical syntheses of the PDKA compounds used in this study are described
in the Supplemental Information. Chemical structures for compounds 1–12 are
shown in Figure S5.
Protein Crystallization, Data Collection, and Data Analysis
Purified C619A GlcB (with His6 tag) at a concentration of 5 mg/ml in 20 mM
Tris-HCl, pH 7.5, buffer with 0.1 M NaCl was mixed for crystallization with an
equal volume of mother liquor of 18%–22% PEG 3350, 0.1 M MgCl2, and
0.1M Tris-HCl, pH 8.0. Crystals were obtained by hanging drop vapor diffusionElsevier Ltd All rights reserved
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crystals into a drop made from mother liquor with 1–5 mM of inhibitor added
from a DMSO stock solution such that the final DMSO concentration was
below 1%, and incubated for 1–5 days. Prior to data collection crystals were
cryo-protected by Fomblin (Sigma) and flash frozen in liquid nitrogen. Data
were collected at Argonne National Lab APS synchrotron, beamlines 19-
and 23-ID, at 0.98 A˚. Diffraction data were indexed, integrated, and scaled
in HKL2000 (Otwinowski and Minor, 1997). Data were truncated in Collabora-
tive Computational Project, Number 4 (1994). 1N8I (Smith et al., 2003) with only
the protein atoms included in the refinement was used as the model for the
initial rigid body refinement of the isomorphous P43212 crystal in REFMAC
(Murshudov et al., 2011). Then iterative runs of inspection and manual modifi-
cation in COOT (Emsley et al., 2010) and refinement in PHENIX (Adams et al.,
2002) with simulated annealing were done to gradually improve themodel. The
ligand model and dictionary files were created in ELBOW BUILDER from the
PHENIX suite and fitted into the density in COOT. Final refinement was done
in BUSTER, Version 2.9. For data collection and refinement statistics see Table
2. All ligands had strong electron density in the 2Fo-Fc map covering all atoms
visible (see example shown in Figure S2). After refinement, the halogens in
halogen-containing inhibitors displayed negative Fo-Fc peaks over them in
the Fourier difference map. This might have been an artifact due to radiation
damage, as refinement with data truncated to very low-redundancy reflections
showed no negative Fo-Fc density at these sites. For final model refinement,
high redundancy sets were used, and individual occupancies were refined
for halogen-containing ligands to eliminate disagreement in the Fo-Fc map.
Ramachandran statistics are as follows (given in order most favored/addition-
ally favored regions/outliers in percentage): GlcB-PDKA, 97.11/2.02/0.87;
GlcB-4, 97.21/1.76/0.73; GlcB-1, 97.34/2.22/0.44; GlcB-7, 97.27/2.16/0.58;
and GlcB-11, 96.85/3.01/0.14. All of the Ramachandran outliers are on the
surface of the protein except Glu273, which hydrogen bonds with a water
molecule coordinating the Mg2+. This unusual backbone conformation is
well supported by the electron density in all data sets.
Whole-Cell Testing
MIC determination was done using the MABA (Franzblau et al., 1998) assay in
96-well plates. For the Mtb mc2-7000 strain (Sambandamurthy et al., 2006),
cells were grown in 7H9 media with OADC supplement (Middlebrook),
0.05% Tyloxapol (Sigma), and 25 mg/ml pantothenate to an optical density
600 (OD600) of 1–2. Then cells were diluted into testing media to an OD600 of
0.01 and pipetted into testing plates, 200 ml per well. The two testing media
were: 7H9 media with 0.2% dextrose, 0.085% NaCl, 0.05% Tyloxapol, and
25 mg/ml pantothenate or M9 (Sigma) media with 0.25% sodium acetate,
2 mM MgSO4, 0.1 mM CaCl2, 0.05% Tyloxapol, and 25 mg/ml pantothenate.
Then each compound was added as a 1/2 serial dilution in DMSO (2%
DMSO final in a well). 7H9-dextrose plates were incubated for 6 days before
staining with resazurin (Sigma), and M9-acetate plates were incubated for
3 weeks and then for an additional 2 days after staining at 37C with shaking.
The lowest concentration where resazurin stayed completely unconvertedwas
recorded as the MIC99 value. MIC99 refers to the minimum concentration at
which growth of the experimental strain mc2-7000 is inhibited by >99%, as
assessed by absence of respiration in the rezasurin (AlamarBlue) assay.
Rifampicin was used as a control: for mc2-7000 Mtb displaying an MIC99 of
0.125 mM in 7H9-dextrose, and anMIC99 of 0.25 mM inM9-acetate. MIC values
for rifampicin varied no more than one dilution point from run to run. All MIC99
values reported are overage with 1/2 dilution precision from at least three
independent experiments. For H37Rv Mtb strain testing, an inoculum stan-
dardized to approximately 1 3 107 CFU 3ml1 was diluted 1 in 200 in testing
media of 7H9, ADC, 0.025% Tween 80, 0.085% NaCl or 7H9, 0.5% albumin,
0.1% sodium acetate, 0.025% Tween 80, 0.085%NaCl. Inhibitors were tested
as with the mc2-7000 strain. Plates were incubated at 37C for 6 days before
and 24–48 hr after staining with resazurin.
Mouse Microsome Clearance and Plasma Protein Binding
Microsomal intrinsic clearance was measured as described by (Clarke and
Jeffrey, 2001). The compound (0.5 mM) was incubated with 0.5 mg/ml
microsomal protein, 0.34 mg/ml NADP, 1.56 mg/ml glucose-6-phosphate,
and 1.2 U/ml glucose-6-phosphate dehydrogenase, 2.6 mg/ml UDPGA,
0.5% (v/v) methanol in 50 mM potassium phosphate buffer, pH 7.4, at 37C.Chemistry & Biology 19, 1556–156Fifty microliter aliquots of the incubation mixture were withdrawn at various
time points over 30 min and added to 100 ml stop solution (80:20:1 (v/v/v) ace-
tonitrile:ethanol:acetic acid) containing internal standard. Samples were snap
frozen and stored at 80C until analyzed by liquid chromatography/tandem
mass spectrometry (LC/MS/MS). Prior to analysis, samples were thawed at
room temperature, vortexed, and then centrifuged, and the supernatant was
taken for analysis. No cofactor controls were included to assess non-P450
dependent clearance. Clearance was estimated for midazolam in parallel to
assure integrity of the microsomal preparations and acceptable interassay
variability. The intrinsic clearance was calculated based on the method
published by (Obach et al., 1997), using the first-order elimination rate
constant for disappearance of the parent compound. This was calculated
from the slope of the log-transformed concentration-time curve using
SigmaPlot 8.0 (Systat Software). Clearances were expressed in milliliters per
minute per gram of liver. The clearance was predicted based on the assump-
tion that the drug concentration (0.5 mM)wasmost likely well below the KM. The
lower limit of quantification was 0.5 ml/min/g liver, and this corresponded to
a <15% decrease in the parent compound in 30 min. The in vitro plasma
protein binding of the diketo acids was determined by equilibrium dialysis
(three cells per species) in fresh mouse and human plasma at 0.5 and
5 mg/ml (0.5% [v/v] DMSO final concentration). Spiked plasma samples
were mixed gently, and triplicate aliquots were collected to verify initial
concentrations. Following assembly of dialysis rapid equilibrium devices
(RED) (Thermo Scientific) (molecular weight cutoff limit of 8,000–10,000 Da),
spiked plasma was placed in the donor compartment of the cell and PBS,
pH 7.4, in the receiver compartment. Cells were incubated in a water bath at
37C and mixed continuously for 6 hr. Triplicate aliquots (volume determined
gravimetrically) from donor and receiver compartments were snap frozen
and stored at 30C prior to analysis. Percent binding was estimated using
standard equations which accounted for volume changes due to Donnan
effects (Boudinot and Jusko, 1984).
Pharmacokinetic Measurement
The compoundwas assayed as a single oral dose at 20mg/kg, 100mg/kg, and
600 mg/kg in female C57BL/6J mice, dissolved in PEG 400/Solutol 70:30. The
sampling scheme postadministration was 15, 30, and 45 min, respectively, at
1, 1.5, 2, 3, 4, and 8 hr; four animals per time point. Peripheral blood levels were
analyzed by LC/MS/MS. Data analysis was performed with WinNonlin 5.2;
noncompartmental analysis (NCA).
Efficacy in Mouse Model of TB
To assess the therapeutic efficacy of compound 12 againstM. tuberculosis in
an acute murinemodel of intratracheal infection (Rullas et al., 2010), mice were
infected with 105 CFU and lung homogenates were obtained 9 days after infec-
tion (n = 4–5 mice per group for all groups). Compound 12 was administered
according to the schedule indicated in Table 4 (either once a day or twice
a day) using PEG 400/Solutol 70:30 as the vehicle. Moxifloxacin (30 mg/kg)
dissolved in Captisol 20% was used as quality control of the assay and
reduced the CFU lung number by 3.07 logs with respect to untreated mice.
The average log CFU in the lungs of untreated mice was 7.13. All mice exper-
iments were done in compliance with GSK regulations.
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Crystal structures of GlcB in complex with inhibitors were deposited in the
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